Related references
Note: Only part of the references are listed.Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery
Yosuke Inoue et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact
Naru Kondo et al.
EUROPEAN JOURNAL OF CANCER (2021)
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial
Davendra P. S. Sohal et al.
JAMA ONCOLOGY (2021)
Pancreatic Adenocarcinoma, Version 2.2021
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol
Yoshihiro Miyasaka et al.
INTERNATIONAL JOURNAL OF SURGERY PROTOCOLS (2021)
Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy A Systematic Literature Review
Teresa Macarulla et al.
PANCREAS (2020)
Surgical Outcome Results From SWOG S1505 A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma
Syed A. Ahmad et al.
ANNALS OF SURGERY (2020)
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
Yoshihiro Miyasaka et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Perioperative Gemcitabine plus Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial
Alice C. Wei et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study
Hiroshi Kurahara et al.
LANGENBECKS ARCHIVES OF SURGERY (2019)
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
Elena Gabriela Chiorean et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact
Yoshiaki Murakami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer
R. Ravikumar et al.
BRITISH JOURNAL OF SURGERY (2017)
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement
Yuichi Nagakawa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Ken-Ichi Okada et al.
ANTICANCER RESEARCH (2017)
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Hideki Ueno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages
Kezhong Tang et al.
PANCREATOLOGY (2016)
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101
Matthew H. G. Katz et al.
JAMA SURGERY (2016)
National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival
Yoshiaki Murakami et al.
WORLD JOURNAL OF SURGERY (2015)
Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation in Patients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma
Pablo E. Serrano et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Neoadjuvant Gemcitabine-based Accelerated Hyperfractionation Chemoradiotherapy for Patients with Borderline Resectable Pancreatic Adenocarcinoma
Yutaka Takeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
Maximilian Bockhorn et al.
SURGERY (2014)
Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery
Hiroyuki Kato et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Arterial Resection During Pancreatectomy for Pancreatic Cancer A Systematic Review and Meta-Analysis
Nathan Mollberg et al.
ANNALS OF SURGERY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Borderline resectable pancreatic cancer: The importance of this emerging stage of disease
Matthew H. G. Katz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey
D Dindo et al.
ANNALS OF SURGERY (2004)
Share Paper
